

Edgar Filing: AMEDISYS INC - Form S-3

AMEDISYS INC
Form S-3
May 23, 2002

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 23, 2002

REGISTRATION NO. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

AMEDISYS, INC.
(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction
of incorporation or organization)

11-3131700
(I.R.S. Employer
Identification Number)

11100 MEAD ROAD, SUITE 300
BATON ROUGE, LOUISIANA 70816
(225) 292-2031
(Address, including zip code, and telephone number, including area code, of
registrant's principal executive offices)

WILLIAM F. BORNE
11100 MEAD ROAD, SUITE 300
BATON ROUGE, LOUISIANA 70816
(225) 292-2031
(Name, address, including zip code, and telephone number, including area code,
of agent for service)

WITH A COPY TO:
ANTHONY J. CORRERO, III
CORRERO FISHMAN HAYGOOD PHELPS WALMSLEY & CASTEIX, L.L.P.
201 ST. CHARLES AVE., 46TH FLOOR
NEW ORLEANS, LOUISIANA 70170-4600
(504) 586-5252

APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: From time
to time after this registration statement becomes effective.

If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. []

If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, please check the following box. [X]

If this Form is filed to register additional securities for an offering

Edgar Filing: AMEDISYS INC - Form S-3

pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. []

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. []

If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. []

CALCULATION OF REGISTRATION FEE

TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED	AMOUNT TO BE REGISTERED (1)	PROPOSED MAXIMUM OFFERING PRICE PER SHARE (2)	PROPOSED MAXIMUM AGGREGATE OFFERING
Common Stock, par value \$.001 per share.....	1,529,000 shares (3)	\$8.32	\$12,000,000

(1) Upon a stock split, stock dividend or similar transaction in the future and during the effectiveness of this Registration Statement involving the registrant's common stock, the total number of shares registered shall be automatically increased to cover the additional shares in accordance with Rule 416(a) under the Securities Act of 1933.

(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based on the average of the high and low prices per share of the registrant's common stock on The Nasdaq SmallCap Market on May 21, 2002.

(3) Of the total number of shares of the registrant's common stock to be registered hereunder, 69,000 shares are issuable upon the exercise of warrants. In addition to the shares set forth in the table above, the amount to be registered includes an indeterminate number of additional shares which may become issuable by virtue of the application of anti-dilution provisions of the warrants.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT THAT SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THIS REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.

THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. THE SELLING SHAREHOLDERS IDENTIFIED IN THIS PROSPECTUS MAY NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE

Edgar Filing: AMEDISYS INC - Form S-3

COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.

SUBJECT TO COMPLETION -- DATED MAY 23, 2002.

PROSPECTUS

[AMEDISYS, INC. LOGO]

AMEDISYS, INC.
11100 MEAD ROAD, SUITE 300
BATON ROUGE, LOUISIANA 70816
(225) 292-2031

1,529,000 SHARES OF COMMON STOCK
OFFERED BY THE SELLING SHAREHOLDERS NAMED HEREIN

This prospectus covers:

- 1,460,000 shares of our common stock owned by shareholders who acquired them from us in a private offering we completed on April 26, 2002; and
- 69,000 shares issuable upon the exercise of warrants to purchase our common stock that were issued in connection with our private offering.

This prospectus may be used by the holders of the shares covered by this prospectus to resell those shares. We refer to those holders in this prospectus as "selling shareholders."

The selling shareholders will receive all of the net proceeds from the sale of the shares of common stock under this prospectus. We will not receive any proceeds from the sale of the shares by the selling shareholders, but we will receive any amounts due to us upon exercise of the warrants. We will pay all the expenses of registration incurred in connection with this offering, but the selling shareholders will pay all selling and other expenses.

The selling shareholders may sell the shares from time to time on The Nasdaq SmallCap Market in regular brokerage transactions, in transactions directly with market makers or in privately-negotiated transactions. For additional information on the methods of sale, see the information under the heading "Plan of Distribution."

Our common stock is listed on The Nasdaq SmallCap Market under the symbol "AMED." On May 22, 2002, the closing price of our common stock was \$8.37 per share.

INVESTING IN OUR SECURITIES INVOLVES CERTAIN RISKS. SEE "RISK FACTORS" BEGINNING ON PAGE 2 OF THIS PROSPECTUS FOR INFORMATION THAT YOU SHOULD CONSIDER BEFORE PURCHASING THESE SHARES.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus is May 23, 2002.

TABLE OF CONTENTS

Edgar Filing: AMEDISYS INC - Form S-3

	PAGE

ABOUT THIS PROSPECTUS.....	i
THE OFFERING.....	1
RISK FACTORS.....	2
Risks Related to Our Substantial Capital Requirements.....	2
Risks Related to Our Working Capital Deficiency.....	2
Risks Related to Change in Medicare Payment Rates.....	2
Risks Related to Our Acquisition Strategy.....	3
Risks Related to Acquisition Financing.....	3
Risks Related to Our Dependence on Management.....	3
Risks Related to Our Exposure to Professional Liabilities.....	3
Risks Related to the Possible Insufficiency of Our Liability Coverage.....	3
Risks Related to Changes in Health Care Regulations and Technology.....	4
Risks Related to Competition.....	4
Risks Related to Our Need for Relationships with Other Organizations.....	4
Risks Related to Federal and State Regulation.....	4
Risks Related to Future Sales of Our Common Stock.....	4
Risks Related to the Possible Adverse Effect of Future Issuances of Our Preferred Stock.....	4
Risks Related to Dilution.....	5
SPECIAL NOTE CONCERNING FORWARD-LOOKING STATEMENTS.....	6
OUR COMPANY.....	7
SELLING SHAREHOLDERS.....	8
PLAN OF DISTRIBUTION.....	12
LEGAL MATTERS.....	13
EXPERTS.....	13
WHERE YOU CAN FIND MORE INFORMATION.....	13
INCORPORATION BY REFERENCE.....	14

You should rely only on the information that is contained in this prospectus or is incorporated by reference in this prospectus. We have not authorized anyone to provide you with information different from that contained in or incorporated by reference in this prospectus. The selling shareholders are offering shares of our common stock and seeking offers to buy such securities only in jurisdictions where such offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock.

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement we filed with the SEC. It is a type of registration statement that is commonly called a "shelf registration" because it permits securities to be offered on a delayed or continuing basis. The selling shareholders can resell the common stock covered by this prospectus at various times determined by each of them. We call these transactions by the selling shareholders resales, because the common stock they may sell under this prospectus was or will be first sold by us to them. We will not receive any proceeds from any of these resales. You should read both this prospectus and the additional information described under the headings "Where You Can Find More Information" and "Incorporation By Reference."

Edgar Filing: AMEDISYS INC - Form S-3

THE OFFERING

Securities Offered by the
Selling Shareholders..... Up to 1,529,000 shares of our common stock, par value \$.001 per share. Of these shares, 1,460,000 were originally sold by us to some of the selling shareholders in a private offering we completed on April 26, 2002. An additional 69,000 shares are issuable upon the exercise of warrants to purchase our common stock. We issued those warrants in connection with our private offering. The selling shareholders may use this prospectus to resell their shares.

Use of Proceeds..... We will not receive any proceeds from sales by the selling shareholders of the shares covered by this prospectus, but we will receive any amounts due to us upon exercise of the warrants.

Our Nasdaq SmallCap Market
Symbol..... AMED

Risk Factors..... Before investing in our common stock by purchasing shares from a selling shareholder, you should carefully read and consider the information set forth in "Risk Factors" and all other information appearing elsewhere and incorporated by reference in this prospectus and any accompanying prospectus supplement.

1

RISK FACTORS

You should carefully consider the risks described below before buying any of our securities. The risks described below are not the only ones facing our company. Additional risks that are now unknown to us or that we now consider immaterial may also harm our business. You should also carefully consider the other information included elsewhere in this prospectus and incorporated into it by reference.

RISKS RELATED TO OUR SUBSTANTIAL CAPITAL REQUIREMENTS

We require substantial capital to pursue our operating strategy, and at December 31, 2001 we had cash and cash equivalents of \$3,515,000. Based on our current plan of operations, we anticipate that our current cash balance, combined with continued profitable operations and the proceeds of the private placement we completed on April 26, 2002, will provide sufficient working capital through December 31, 2002.

We maintain an asset-based line of credit with availability, depending on collateral, of up to \$25 million with National Century Financial Enterprises, or "NCFE", and borrowings under a revolving bank line of credit of up to \$2,500,000. The NCFE \$25 million asset-based line of credit, which expires December, 2003, is collateralized by eligible accounts receivable of the home health care nursing division. Eligible receivables are defined as receivables, exclusive of workers' compensation and self-pay, that are aged less than 181 days. The effective interest rate on this line of credit, which had outstanding balances at December 31, 2001 and 2000 of \$8,593,000 and \$2,952,000,

Edgar Filing: AMEDISYS INC - Form S-3

respectively, was 11.00% and 15.29% for the years ended December 31, 2001 and 2000, respectively. The revolving bank line of credit of \$2,500,000 bears interest at the Bank One Prime Floating Rate, which was 4.75% and 9.5% at December 31, 2001 and 2000, respectively. The bank line of credit expires September 21, 2002 and is collateralized by \$2.5 million in cash. At December 31, 2001 and 2000, there was a balance outstanding of \$712,000 and \$0, respectively.

RISKS RELATED TO OUR WORKING CAPITAL DEFICIENCY

At December 31, 2001, we had a working capital deficit of \$18,360,000. \$7,400,000 of the deficit is related to payments received by us from Medicare related to the Benefit Improvement Protection Act, or "BIPA", which provided a one-time payment to healthcare providers. Although not guaranteed, Medicare has traditionally granted similar, and we expect to receive, extended repayment terms related to the \$7,400,000 advance, and to begin making payments in the third quarter of 2002. Additionally, \$3,100,000 of the deficit is related to Medicare payables of a bankrupt subsidiary. Although the outcome of the bankruptcy is not guaranteed, we do not expect that we will be responsible for repaying the debt of our subsidiary. For more information regarding this and other risk factors, please refer to our Annual Report on Form 10-K for the year ended December 31, 2001.

RISKS RELATED TO CHANGE IN MEDICARE PAYMENT RATES

With the introduction of the Medicare Prospective Payment System, or "PPS", the method of reimbursement under the Medicare program was changed from a cost-based reimbursement system to a prospective payment system based on "episodes of care." An episode of care is defined as a length of care up to sixty days with multiple continuous episodes allowed. At the beginning of PPS on October 1, 2000, the standard episode payment was established at \$2,115 per episode, to be adjusted by certain factors and intervening events. BIPA provided for the following: (i) a one-year delay in applying the budgeted 15% reduction on payment limits, (ii) the restoration of a full home health market basket update for episodes ending on or after April 1, 2001 and before October 1, 2001 resulting in an increase to revenues of 2.2%, (iii) a 10% increase, beginning April 1, 2001 and extending for a period of twenty four months, for home health services provided in a rural area, and (iv) a one-time payment equal to two months of periodic interim payments.

Effective October 1, 2001 with the beginning of federal fiscal year 2002, the standard episode payment was increased to \$2,274. Currently, the delay in the budgeted 15% reduction in payment limits resulting from BIPA will expire September 30, 2002. There is ongoing debate and discussion in Congress concerning the scheduled payment reduction, which was further intensified with the recommendation by the Medicare

2

Payment Advisory Committee to eliminate the budgeted 15% payment reduction. In addition to the 15% scheduled reduction, the provision in BIPA under which home health care providers received a 10% increase in reimbursement for service provided in a rural area is scheduled to expire March 31, 2003. For more information regarding this and other risk factors, please refer to our Annual Report on Form 10-K for the year ended December 31, 2001.

RISKS RELATED TO OUR ACQUISITION STRATEGY

We intend to grow significantly through the acquisition of additional home health care and complementary businesses. We expect to face competition for acquisition candidates, which may limit the number of acquisition opportunities and may lead to higher acquisition prices. There can be no assurance that we

Edgar Filing: AMEDISYS INC - Form S-3

will be able to identify, acquire or manage profitably additional businesses or to integrate any acquired businesses into our existing operations without substantial costs, delays or other operational or financial problems. Further, acquisitions involve a number of risks, including possible adverse effects on our operating results, diversion of management's attention, failure to retain key personnel of the acquired business and risks associated with unanticipated events or liabilities, some or all of which could have a material adverse effect on our business, financial condition and results of operations. While we continually identify acquisition targets, we have not targeted a specific acquisition for the proceeds of our April 26, 2002 private offering and we have not developed specific criteria for use in connection with further acquisitions.

RISKS RELATED TO ACQUISITION FINANCING

We cannot readily predict the timing, size and success of our acquisition efforts and the associated capital commitments. If we do not have sufficient cash resources, our growth could be limited unless we are able to obtain additional equity or debt financing.

RISKS RELATED TO OUR DEPENDENCE ON MANAGEMENT

Our success depends upon our management, including our Chief Executive Officer, William F. Borne. We maintain key employee life insurance in the amount of \$4.5 million on the life of Mr. Borne and entered into an employment agreement with Mr. Borne. The loss of Mr. Borne's services could materially adversely affect our operations.

RISKS RELATED TO OUR EXPOSURE TO PROFESSIONAL LIABILITIES

Due to the nature of our business, we and certain nurses who provide services on our behalf may be the subject of medical malpractice claims, with the attendant risk of substantial damage awards. We could be exposed to liability based on the negligence of nurses caring for our home health patients. To the extent these nurses are regarded as our agents in the practice of nursing, we could be held liable for any medical negligence of them. There can be no assurance that a future claim or claims will not exceed the limits of available insurance coverage or that such coverage will continue to be available.

RISKS RELATED TO THE POSSIBLE INSUFFICIENCY OF OUR LIABILITY COVERAGE

We maintain professional liability insurance covering us and our subsidiaries. However, there can be no assurance that any such claims will not be made in the future in excess of the limits of such insurance, if any, or that any such claims, if successful and in excess of such limits, will not have a material adverse effect on our assets and our ability to conduct our business. There can be no assurance that we will continue to maintain such insurance or that such insurance can be maintained at acceptable costs. Our insurance coverage currently includes fire, property damage and general liability with a \$1,000,000 limit on each wrongful act and a \$3,000,000 limit in aggregate. There can be no assurance that any claim will be within the scope of our coverage or that such claims will not exceed our coverage.

RISKS RELATED TO CHANGES IN HEALTH CARE REGULATIONS AND TECHNOLOGY

There can be no assurance that we will not be adversely affected by future possible changes in medical and health regulations, the use, cost and availability of hospitals and other health care services, and medical technological developments.

Edgar Filing: AMEDISYS INC - Form S-3

RISKS RELATED TO COMPETITION

The business in which we operate is highly competitive. We compete with hospitals, nursing homes, and other businesses that provide home health care services, many of which are large and established companies with significantly greater resources than ours.

RISKS RELATED TO OUR NEED FOR RELATIONSHIPS WITH OTHER ORGANIZATIONS

The development and growth of our business depends to a significant extent on our ability to establish close working relationships with health maintenance organizations, preferred provider organizations, hospitals, clinics, nursing homes, physician groups, and other health care providers. Although we have established such relationships, there is no assurance that we will successfully maintain existing relationships and that we can successfully develop and maintain additional relationships in existing and future markets.

RISKS RELATED TO FEDERAL AND STATE REGULATION

The healthcare industry is subject to numerous laws and regulations of the federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in a provider's expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed.

Our management believes that we are in compliance with all state and federal legal provisions concerning fraud and abuse as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with these laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time.

The Health Insurance Portability and Accountability Act, or HIPAA, was enacted on August 21, 1996 to assure health insurance portability, reduce healthcare fraud and abuse, guarantee security and privacy of health information and enforce standards for health information. Organizations are required to be in compliance with certain HIPAA provisions beginning in October 2002. Provisions not yet finalized are required to be implemented two years after the effective date of the regulation. Organizations are subject to significant fines and penalties if found not to be compliant with the provisions outlined in the regulations. Our management is in the process of evaluating the impact of this legislation on our operations, including future financial and operational enhancements that will be required to comply with the legislation.

RISKS RELATED TO FUTURE SALES OF OUR COMMON STOCK

Sales of our common stock in the public market may have a depressive effect on prevailing market prices for our common stock. There is no assurance that the public market for the common stock will not be volatile, sporadic or limited. Accordingly, you may not be able to resell shares of common stock at or above your respective purchase price, and you may not be able to liquidate your investment even at a loss without considerable delay.

RISKS RELATED TO THE POSSIBLE ADVERSE EFFECT OF FUTURE ISSUANCES OF OUR PREFERRED STOCK

Edgar Filing: AMEDISYS INC - Form S-3

Our certificate of incorporation authorizes us to issue 5,000,000 shares, par value \$.001 per share, of "blank check" preferred stock with such designations, rights and preferences as our board of directors may

4

determine from time to time. Accordingly, our board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting, or other rights that could adversely affect the voting power or other rights of the holders of the common stock. In the event of an additional issuance, the preferred stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of our company. We have no present intention to issue any additional shares of our preferred stock. However, there can be no assurance that we will not issue additional preferred stock at some time in the future.

RISKS RELATED TO DILUTION

On May 22, 2002, there were 8,866,117 shares of our common stock outstanding and no shares of our preferred stock outstanding. In connection with our private offering to some of the selling shareholders of 1,460,000 of the shares covered by this prospectus, we issued warrants to purchase 69,000 shares of our common stock to the placement agents for the offering and the designees of one placement agent. In addition, as of May 22, 2002, we had outstanding additional warrants to purchase 289,720 shares of our common stock and options to purchase 913,363 shares of our common stock. If any of the warrants or options are exercised, you will experience dilution of your shares.

5

SPECIAL NOTE CONCERNING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements. Forward-looking statements include, among other things, the discussions of our operations, margins, profitability, liquidity and capital resources. Although we believe that the expectations reflected in forward-looking statements are reasonable, we can give no assurance that such expectations will prove to have been correct. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of such plans or strategies, or projections involving anticipated revenues, expenses, earnings, levels of capital expenditures, liquidity or indebtedness or other aspects of operating results or financial position.

All phases of our operations are subject to a number of uncertainties, risks and other influences, many of which are outside our control and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements we have made ultimately prove to be accurate. Important factors that could cause actual results to differ materially from our expectations are disclosed in "Risk Factors."

6

OUR COMPANY

We are a leading multi-regional provider of home health care nursing services. We operate 57 home care nursing offices and two corporate offices in the southern and southeastern United States.

During 1999, we changed our strategy from providing a variety of alternate

Edgar Filing: AMEDISYS INC - Form S-3

site provider health care services to becoming a leader in home health care nursing services. Our change of focus was largely due to our significant investment in this segment of the industry through our acquisition of 83 home care offices from Columbia/HCA Healthcare Corporation in late 1998. A second major factor was the anticipated implementation in October 2002 of the Prospective Payment System, or "PPS", under Medicare that will now allow home care providers the opportunity to be more profitable. A third significant factor was our belief that we had established a reputation and have expertise in the field.

Pursuant to this strategy, we launched a restructuring plan to divest our non-home health care nursing divisions. During the period from September 1999 through September 2001, we sold and/or closed our surgery centers and infusion divisions. We plan to achieve a major market presence in home health care nursing services in the southern and southeastern United States by expanding our referral base through the use of a highly trained sales force, offering specialized programs such as wound care, and completing selective acquisitions. We cannot guarantee that we will be able to achieve this goal.

We are continuing to systematically reduce operating costs by converting our method of nurse pay to a variable or per-visit rate rather than a fixed or salary system, utilizing economies of scale, and reducing corporate overhead. We have outsourced business functions that we do not consider to be part of our core business and have streamlined our management layers.

We have developed our business model to promote success under PPS. We have implemented disease state management programs and clinical protocols as well as supporting technology to monitor and report outcome data, to standardize care, and to ensure quality outcomes. Using clinical managers to assess and track patient progress and skilled nurses to deliver care are also important components of our overall plan.

We were incorporated in Louisiana in 1982. In 1993, we became a publicly traded company through a merger with M & N Capital, a New York corporation. In 1994, we changed our state of incorporation from New York to Delaware. Our common stock trades on The Nasdaq SmallCap Market under the symbol "AMED."

7

SELLING SHAREHOLDERS

Of the total number of shares of our common stock covered by this prospectus, 1,460,000 shares were acquired by some of the selling shareholders in a private offering that we completed on April 26, 2002. An additional 69,000 shares are issuable upon the exercise of warrants to purchase our common stock. We issued the warrants to the placement agents that conducted the private offering and the designees of one placement agent. Also in connection with that offering, we agreed to file, on behalf of the selling shareholders, a registration statement with the SEC covering the shares. Each of the selling shareholders has elected to exercise his, her or its registration rights. This prospectus is a part of the registration statement that we filed with the SEC covering the shares. The selling shareholders may use this prospectus to resell the shares from time to time under Rule 415 under the Securities Act of 1933. See "Plan of Distribution."

We have agreed to file such amendments and supplements to the registration statement and the prospectus as may be necessary to keep the registration statement effective until the earlier of:

- the date that all of the shares covered by this prospectus have been sold under the registration statement of which this prospectus is a part; and

Edgar Filing: AMEDISYS INC - Form S-3

- the date that the selling shareholders receive an opinion of our counsel that they may sell the shares covered by this prospectus, without limitation or restriction as to quantity or timing and without registration under the Securities Act, pursuant to Rule 144(k) under the Securities Act or otherwise.

The following table sets forth information about the selling shareholders and the number of shares of our common stock that are or will be beneficially owned by each of them prior to the offering, including the shares offered hereby for each selling shareholder's account. We cannot estimate the number or percentage of the shares of common stock that will be held by each selling shareholder upon completion of this offering because the selling shareholders may sell all or some portion of the shares offered by this prospectus. We do not know when or in what amounts the selling shareholders may offer shares for resale, and cannot be certain that the selling shareholders will sell any or all of the shares offered by this prospectus.

SELLING SHAREHOLDERS -----	NUMBER OF SHARES BENEFICIALLY OWNED OR SUBJECT TO WARRANTS PRIOR TO THE OFFERING (AS OF THE DATE OF THIS PROSPECTUS) -----	NUMBER OF SHARES OFFERED IN THIS PROSPECTUS -----
Conus Fund L.P. c/o Conus Partners One Rockefeller Plaza, 19th Floor New York, NY 10020	42,100	42,100
East Hudson Inc. c/o Conus Partners One Rockefeller Plaza, 19th Floor New York, NY 10020	14,500	14,500
The Conus Fund Offshore Ltd. c/o Conus Partners One Rockefeller Plaza, 19th Floor New York, NY 10020	8,400	8,400
Duck Partner, L.P. c/o Hull Capital 750 Lexington Avenue, 26th Floor New York, NY 10022	10,000	10,000
Hull Associates L.P. c/o Hull Capital 750 Lexington Avenue, 26th Floor New York, NY 10022	15,000	15,000

SELLING SHAREHOLDERS -----	NUMBER OF SHARES BENEFICIALLY OWNED OR SUBJECT TO WARRANTS PRIOR TO THE OFFERING (AS OF THE DATE OF THIS PROSPECTUS) -----	NUMBER OF SHARES OFFERED IN THIS PROSPECTUS -----
C.S.L. Associates L.P.	43,000	43,000

Edgar Filing: AMEDISYS INC - Form S-3

399 Park Avenue, 37th Floor New York, NY 10022 J.W. Focused Growth Fund, L.P.	7,000	7,000
c/o Schottenfeld Associates 399 Park Avenue, 37th Floor New York, NY 10022 Blanco Partners, L.P.	10,000	10,000
c/o Kercheville & Co. 15750 IH 10W Loop 16 San Antonio, TX 78249 Ellen W. Johnston.....	10,000	10,000
c/o Bank of Bermuda 23805 Stuart Ranch Road, Suite 105 Malibu, CA 90265 Rosebury L.P.	19,000	19,000
c/o Guild Investment Management, Inc. 23805 Stuart Ranch Road, Suite 105 Malibu, CA 90265 Metoric, L.P.	21,000	21,000
c/o Guild Investment Management, Inc. 23805 Stuart Ranch Road, Suite 105 Malibu, CA 90265 The D3 Family Fund, L.P.	720,000	720,000
19605 Northeast 8th St. Camas, WA 98607-9252 Henry E. Hooper.....	1,500	1,500
19605 N.E. 8th St. Camas, WA 98607-9252 James A. Lawrence.....	24,000	24,000
4415 East Lake Harriet Parkway Minneapolis, MN 55409 Jeffrey D. Zients.....	40,000	40,000
4720 Woodway Lane, N.W. Washington, DC 20016 Michael A. D'Amato.....	40,000	40,000
1862 Brothers Road Vienna, VA 22182 Alan B. Zients.....	25,000	25,000
1056 Fifth Avenue, Apt. 20E New York, NY 10028 Olivier Roux.....	10,000	10,000
c/o Nierenberg Investment Management Co., Inc. 19605 N.E. 8th St. Camas, WA 98607-9252 Peter van Oppen.....	36,500	36,500
5257 Forest Ave., S.E. Mercer Island, WA 98040		

9

SELLING SHAREHOLDERS	NUMBER OF SHARES BENEFICIALLY OWNED OR SUBJECT TO WARRANTS PRIOR TO THE OFFERING (AS OF THE DATE OF THIS PROSPECTUS)	NUMBER OF SHARES OFFERED IN THIS PROSPECTUS
-----	-----	-----

Edgar Filing: AMEDISYS INC - Form S-3

Haredale Ltd.	24,500	24,500
c/o Nierenberg Investment Management Co., Inc. 19605 N.E. 8th St. Camas, WA 98607-9252		
James Henry Hildenbradt.....	7,000	7,000
c/o Nierenberg Investment Management Co., Inc. 19605 N.E. 8th St. Camas, WA 98607-9252		
Toxford Corp.	4,000	4,000
c/o Nierenberg Investment Management Co., Inc. 19605 N.E. 8th St. Camas, WA 98607-9252		
London Family Trust.....	10,000	10,000
212 Aurora Dr. Montecito, CA 93109		
The Pinnacle Fund, L.P.	287,000	37,000
4965 Preston Park Blvd., Suite 240 Plano, TX 75093-5170		
Judi Schindler.....	5,000	5,000
4701 Northside Dr. Atlanta, GA 30327		
Westpark Capital, L.P.	2,500	2,500
c/o The Wespark Fund 4965 Preston Park Blvd., Suite 220 Plano, TX 75092		
Southwell Partners, L.P.	160,000	26,500
1901 North Akard St. Dallas, TX 75201		
J. Steven Emerson IRA R/O II.....	100,000	50,000
Bear Stearns Securities Corp. Custodian 1999 Avenue of the Stars, Suite 2530 Los Angeles, CA 90067		
Glacier Partners.....	71,500	15,000
c/o Glacier Capital 3375 Foothill Road, Suite 523 Carpinteria, CA 93013		
DHL Capital Management.....	25,000	25,000
880 Third Ave., 16th Floor New York, NY 10022		
Ponte Vedra Partners Ltd.	14,000	14,000
1548 The Greens Way, Suite 6 Jacksonville Beach, FL 32250		
Dolphin Offshore Partners, L.P.	60,000	60,000
129 East 17th St. New York, NY 10003		
Smoke Holdings.....	36,000	36,000
Holt Homes P.O. Box 87970 Vancouver, WA 98687		

Edgar Filing: AMEDISYS INC - Form S-3

SELLING SHAREHOLDERS	OWNED OR SUBJECT TO WARRANTS PRIOR TO THE OFFERING (AS OF THE DATE OF THIS PROSPECTUS)	NUMBER OF SHARES OFFERED IN THIS PROSPECTUS
William M. Sams..... 326 Mantle Brook Drive Desoto, TX 75115	15,000	15,000
Michael M. Howard..... 100 Gordon Pond Lane Fairfield, CT 06430	7,500	7,500
Schuyler F. Hoss and..... Rhona S. Hoss 3501 Southeast 168th Ave. Vancouver, WA 98683	14,000	14,000
Charles Schwab & Co. Inc. FBO..... Schuyler F. Hoss IRA 3501 Southeast 168th Ave. Vancouver, WA 98683	10,000	10,000
Belle Haven Investments, L.P. 5 Greenwich Office Park Greenwich, CT 06831	116,000 (1)	26,000
Sanders Morris Harris..... 8750 North Central Expressway Ste. 930 Dallas, TX 75231	4,500	4,500
Gary Glaser..... 5 Greenwich Office Park Greenwich, CT 06831	26,000	26,000
Joanne Kennedy..... 5 Greenwich Office Park Greenwich, CT 06831	12,500	12,500

(1) Includes 26,000 shares subject to warrants to purchase our common stock, and 90,000 shares that Belle Haven is deemed to beneficially own by virtue of its exercise of discretionary authority over a customer's account.

None of the selling shareholders named above has held or had any position, office, or other material relationship with us or any of our predecessors or our affiliates within the last three years, except that Belle Haven Investments, L.P. and Sanders Morris Harris served as placement agents for our private placement that we completed on April 26, 2002. Gary Glaser and Joanne Kennedy are principals of Belle Haven Investments. In connection with that offering, we issued to Belle Haven Investments, Sanders Morris Harris, Mr. Glaser and Ms. Kennedy warrants to purchase a total of 69,000 shares of our common stock. Those 69,000 shares are the shares offered by Belle Haven Investments, Sanders Morris Harris, Mr. Glaser and Ms. Kennedy under this prospectus.

Only selling shareholders identified above who beneficially own the shares set forth opposite such selling shareholder's name in the table above on the effective date of the registration statement of which this prospectus forms a part may sell those securities under the registration statement.

Edgar Filing: AMEDISYS INC - Form S-3

The selling shareholders may sell shares of our common stock directly, through broker-dealers acting as principal or agent or pursuant to a distribution by one or more underwriters on a firm commitment or best efforts basis. The selling shareholders may sell all or part of their shares in one or more transactions at prices at or related to the then-current market price or at negotiated prices. The selling shareholders will determine the specific offering price of the shares from time to time that, at that time, may be higher or lower than the market price of our common stock on The Nasdaq SmallCap Market or other securities market.

In connection with any underwritten offering, underwriters and their agents may receive compensation in the form of discounts, commissions or concessions from the selling shareholders or from purchasers of shares for whom they act as agents. Underwriters may sell shares to or through dealers, and those dealers may receive compensation in the form of discounts, commissions or concessions from the underwriters or commissions from the purchasers for whom they may act as agents. The selling shareholders and any underwriters, dealers or agents participating in the distribution of the shares of our common stock may be deemed to be "underwriters" within the meaning of the Securities Act, and any profit from the sale of these shares by the selling shareholders and any compensation received by any underwriter, broker-dealer or agent may be deemed to be underwriting discounts under the Securities Act.

The method by which the selling shareholders may offer and sell their shares may include, but are not limited to, the following:

- sales on any securities exchange on which our common stock is listed at the time of sale, or through quotation systems in which our common stock is included, at prices and terms then prevailing or at prices related to the then-current market price;
- sales in privately negotiated transactions;
- sales for their own account pursuant to this prospectus;
- cross or block trades in which broker-dealers will attempt to sell the shares as agent, but may position and resell a portion of the block as a principal to facilitate the transaction;
- purchases by broker-dealers who then resell the shares for their own account; and
- brokerage transactions in which a broker solicits purchasers.

To the extent required by a particular offering, we will set forth in a prospectus supplement or, if appropriate, a post-effective amendment, the terms of the offering, including among other things, the number of shares of our common stock to be sold, the public offering price, the names of any underwriters, dealers or agents and any applicable commissions or discounts.

In order to comply with the securities laws of particular states, if applicable, the shares of our common stock offered under this prospectus will be sold in the jurisdictions only through registered or licensed brokers or dealers. In addition, in particular states, the shares of our common stock may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirements is available and is complied with.

Each selling shareholder will be subject to applicable provisions of the Securities Exchange Act of 1934 and the rules and regulations thereunder, which provisions may limit the timing of purchases and sales of shares of common stock by the selling shareholders.

Edgar Filing: AMEDISYS INC - Form S-3

We have agreed to indemnify the selling shareholders, and the selling shareholders have agreed to indemnify us, against certain liabilities, including liabilities under the Securities Act.

Each selling shareholder will pay all fees, discounts and brokerage commissions allocable to his, her or its shares, as well as the fees and expenses of his, her or its counsel. We will pay all expenses of this registration, including without limitation, the costs and expenses of preparing and reproducing this prospectus and complying with state securities laws, as well as filing fees with the SEC.

12

LEGAL MATTERS

Michael Lutgring, our counsel and former Executive Vice President, has given us an opinion that the shares have been duly authorized, and that they are, or in the case of the shares issuable upon exercise of warrants will be, validly issued, fully paid and non-assessable.

EXPERTS

The consolidated financial statements and schedules incorporated by reference in this prospectus and elsewhere in the registration statement have been audited by Arthur Andersen LLP, independent public accountants, as indicated in their report with respect thereto, and are included herein in reliance upon the authority of said firm as experts in accounting and auditing in giving said reports.

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any document we file at the SEC's public reference room located at 450 Fifth Street, N.W., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. Our SEC filings are also available to the public from commercial document retrieval services and at the web site maintained by the SEC at: <http://www.sec.gov>. Reports, proxy statements and other information pertaining to us may also be inspected at the offices of The Nasdaq Stock Market, which is located at 1735 K Street, N.W., Washington, D.C. 20006.

This prospectus is part of a registration statement on Form S-3 that we have filed with the SEC to register the securities offered by this prospectus. The registration statement contains additional information about us and our securities. You may inspect the registration statement and exhibits at the SEC public reference room or at the SEC's website. As allowed by the SEC rules, this prospectus does not contain all of the information you can find in our registration statement or the exhibits to the registration statement.

You should rely only on the information or representations provided in this prospectus or any supplement to this prospectus. We have not authorized anyone else to provide you with different information. The selling shareholders may not make an offer of our securities in any state where the offer is not permitted. The delivery of this prospectus does not, under any circumstances, mean that there has not been a change in our affairs since the date of this prospectus. It also does not mean that the information in this prospectus is correct after this date.

Our address on the world wide web is <http://www.amedisys.com>. The information on our web site is not a part of this document.

Edgar Filing: AMEDISYS INC - Form S-3

13

INCORPORATION BY REFERENCE

The SEC allows us to "incorporate by reference" the information we file with it, which means that we can disclose important information to you by referring to documents that we have filed with the SEC. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC will automatically update and supersede this incorporated information.

We incorporate by reference the documents listed below and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 until the completion of the offering of the securities described in this prospectus:

FILINGS -----	PERIOD OR DATE FILED -----
Our Annual Report on Form 10-K.....	Year ended December 31, 2001
Our Quarterly Report on Form 10-Q.....	March 31, 2002
Our Current Reports on Form 8-K.....	March 6, 2002, April 29, 2002 and May 3, 2002
Our Amendment to Current Report on Form 8-K.....	May 13, 2002
Our Definitive Proxy Statement on Schedule 14A.....	April 30, 2002
The description of our common stock set forth in our Current Report on Form 8-K.....	December 11, 2000

In addition to the filings listed above, we incorporate by reference additional documents that we may file with the SEC between the date of this document and the date of the completion of the offering of the securities described in this prospectus. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.

You can obtain any of the documents incorporated by reference in this document from us, or from the SEC through the SEC's Internet world wide web site at <http://www.sec.gov>. Documents incorporated by reference are available from us without charge, excluding any exhibits to those documents, unless the exhibit is specifically incorporated by reference as an exhibit in this document. You can obtain documents incorporated by reference in this document upon written or oral request to us at the following address:

Amedisys, Inc.
11100 Mead Road
Suite 300
Baton Rouge, Louisiana 70816
(225) 292-2031

We have not authorized anyone to give any information or make any representation about the offering or us that is different from, or in addition to, that contained in this document. Therefore, if anyone does give you information of that sort, you should not rely on it. The information contained in this document speaks only as of the date of this document unless the

Edgar Filing: AMEDISYS INC - Form S-3

information specifically indicates that another date applies.

Any statement contained in a document incorporated or deemed incorporated herein by reference shall be deemed to be modified or superseded for the purpose of this prospectus to the extent that a statement contained herein or in any subsequently filed document which also is, or is deemed to be, incorporated herein by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as to modified or superseded, to constitute a part of this prospectus.

14

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

The following are the fees and expenses payable by the registrant in connection with the offering contemplated by the registration statement, all of which are estimated except the registration fee.

Securities and Exchange Commission registration fee.....	\$ 1,170.36
Printing Expenses.....	5,000.00
Legal fees and expenses.....	15,000.00
Accounting fees and expenses.....	5,000.00
Miscellaneous.....	1,000.00

Total.....	\$27,170.36

The selling shareholders have not paid, and are not responsible for, any portion of these fees and expenses.

ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

The Delaware General Corporation Law (the "statute"), Section 145, gives Delaware corporations broad powers to indemnify their present and former directors, officers, agents and employees and those of affiliated corporations against expenses incurred in the defense of any lawsuit to which they are, or might be, made parties by reason of being, or having been, such directors, officers, agents or employees; subject to specific conditions and exclusions gives a director, officer, agent or employee who successfully defends an action the right to be so indemnified, and in some cases permits even those who unsuccessfully defend actions to be so indemnified; and authorizes Delaware corporations to buy liability insurance on behalf of any current or former director, officer, agent or employee. Such indemnification is not exclusive of any other rights to which those indemnified may be entitled under any by-law, agreement, authorization of shareholders or otherwise.

Article XI of the Certificate of Incorporation of the registrant provides for indemnification of officers, directors, agents and employees of the registrant as follows:

- (a) The Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation)

Edgar Filing: AMEDISYS INC - Form S-3

by reason of the fact that he is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner in which he reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful.

(b) The Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys' fees) actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if he acted in good faith and in a manner he reasonably believed to be in

II-1

or not opposed to the best interests of the Corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

(c) To the extent that a director, officer, employee or agent of the Corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (a) and (b) of this Article, or in defense of any claim, issue or matter therein, he shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by him in connection therewith.

(d) Any indemnification under subsections (a) and (b) of this Article (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances because he has met the applicable standard of conduct set forth in subsections (a) and (b) of this Article. Such determination shall be made (1) by the Board of Directors by a majority vote of a quorum consisting of directors who were not parties to such action, suit or proceeding, or (2) if such quorum is not obtainable, or, even if obtainable a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, or (3) by the stockholders.

(e) Expenses (including attorneys' fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative

Edgar Filing: AMEDISYS INC - Form S-3

action, suit or proceeding may be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified by the Corporation as authorized by this Article. Such expenses (including attorneys' fees) incurred by other employees and agents may be so paid upon such terms and conditions, if any, as the Board of Directors deems appropriate.

(f) The indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this Article shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office.

(g) The Corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the Corporation would have the power to indemnify him against such liability under this Article.

(h) For purposes of this Article references to "the Corporation" shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had the power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under this Article with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued.

(i) The indemnification and advancement of expenses provided by, or granted pursuant to, this Article shall, unless otherwise provided when authorized and ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

II-2

The foregoing discussion of the Company's Certificate of Incorporation and of the statute is not intended to be exhaustive and is qualified in its entirety by such Certificate of Incorporation and the statute, respectively.

ITEM 16. EXHIBITS.

The following documents are filed herewith or incorporated by reference herein:

EXHIBIT

Edgar Filing: AMEDISYS INC - Form S-3

NO.	DESCRIPTION
4.1	Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 filed with the registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2002).
4.2	By-Laws of the registrant (incorporated by reference to Exhibit 3.2 filed with the registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2001).
4.3	Shareholder Rights Agreement, dated June 15, 2000 (incorporated by reference to Exhibit 4(i) filed with the registrant's Current Report on Form 8-K filed on June 16, 2000).
4.4	Registration Rights Agreement dated as of April 23, 2002 by and between Amedisys, Inc. and the investors listed on Schedule I thereto.
4.5	Registration Rights Agreement dated as of April 23, 2002 by and between Amedisys, Inc. and Belle Haven Investments, L.P.
5.1	Opinion of Michael D. Lutgring, counsel to the registrant, regarding the validity of the securities registered hereby.
23.1	Consent of Arthur Andersen LLP.
23.2	Consent of Michael D. Lutgring, counsel to the registrant, (included in Exhibit 5.1).
24	Power of Attorney (included in the signature page to this registration statement).

ITEM 17. UNDERTAKINGS.

(a) The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange

Edgar Filing: AMEDISYS INC - Form S-3

Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the

II-3

securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

II-4

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned thereunto duly authorized, in the City of Baton Rouge, State of Louisiana, on May 23, 2002.

AMEDISYS, INC.

By: /s/ WILLIAM F. BORNE

William F. Borne
Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS that each person whose signature appears below constitutes and appoints William F. Borne, his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated on May 23, 2002.

SIGNATURE

TITLE

/s/ WILLIAM F. BORNE

William F. Borne

Chief Executive Officer and Chairman of the Board
(Principal Executive Officer)

Edgar Filing: AMEDISYS INC - Form S-3

/s/ LARRY R. GRAHAM ----- Larry R. Graham	Interim Chief Financial Officer (Principal Financial and Accounting Officer)
/s/ JAKE L. NETTERVILLE ----- Jake L. Netterville	Director
----- David R. Pitts	Director
----- Peter F. Ricchiuti	Director
/s/ RONALD A. LABORDE ----- Ronald A. Laborde	Director

II-5

INDEX TO EXHIBITS

EXHIBIT NO. -----	DESCRIPTION -----
4.1	Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 filed with the registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2002).
4.2	By-Laws of the registrant (incorporated by reference to Exhibit 3.2 filed with the registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2001).
4.3	Shareholder Rights Agreement, dated June 15, 2000 (incorporated by reference to Exhibit 4(i) filed with the registrant's Current Report on Form 8-K filed on June 16, 2000).
4.4	Registration Rights Agreement dated as of April 23, 2002 by and between Amedisys, Inc. and the investors listed on Schedule I thereto.
4.5	Registration Rights Agreement dated as of April 23, 2002 by and between Amedisys, Inc. and Belle Haven Investments, L.P.
5.1	Opinion of Michael D. Lutgring, counsel to the registrant, regarding the validity of the securities registered hereby.
23.1	Consent of Arthur Andersen LLP.
23.2	Consent of Michael D. Lutgring, counsel to the registrant, (included in Exhibit 5.1).
24	Power of Attorney (included in the signature page to this registration statement).

